Medera Inc. is a clinical-stage biotechnology company focused on developing treatments for difficult-to-treat cardiovascular diseases through next-generation AAV gene therapy. We leverage our bioengineered human "mini-Heart"platform for disease modeling, preclinical screening, and drug discovery and our proprietary intracoronary delivery technology to address major challenges associated with gene therapy. Led by world-renowned pioneers in cell and gene therapy for cardiovascular disease, we have developed a pipeline comprised of treatments for highly prevalent indications, such as heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), as well as orphan disease like Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM). Our HFpEF and HFrEF programs have demonstrated promising human proof-of-concept in Phase 1/2 trials, and we have recently initiated a Phase 1/2 trial for DMD-CM with interim data expected in mid-2026.